| Zhang, Wenhua |
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients |
|
|
| Recruiting | 4 | 5000 | RoW | Peginterferon Alfa-2B, Nucleoside Analogs | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis B, Chronic | 12/26 | 11/29 | | |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/26 | 12/26 | | |
NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) |
|
|
| Recruiting | 2 | 120 | RoW | TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-alcoholic Steatohepatitis | 12/26 | 12/27 | | |
NCT06566248: A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B |
|
|
| Recruiting | 2 | 90 | RoW | TQA3810 tablets+NUC, Placebo+NUC | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Hepatitis B | 09/24 | 03/25 | | |
TQB2618-AK105-Ib-04, NCT05975645: A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). |
|
|
| Recruiting | 1 | 40 | RoW | Penpulimab injection, TQB2618 injection, Anlotinib Hydrochloride Capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma | 12/24 | 04/25 | | |
| Nie, Peng S |
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer |
|
|
| Active, not recruiting | 3 | 878 | RoW | JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy | Shanghai Junshi Bioscience Co., Ltd. | Gastric or Esophagogastric Junction Adenocarcinoma | 06/26 | 07/28 | | |
NCT05246982: HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer |
|
|
| Recruiting | 2 | 40 | RoW | HLX07+HLX10+oxaliplatin+capecitabine, HLX07 | Shanghai Henlius Biotech | Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ) | 12/23 | 03/24 | | |
NCT05494359: The Diagnostic Value of Nitrogen Element (N) in Esophagus Cancer |
|
|
| Recruiting | N/A | 120 | RoW | The nitrogen isotope | Hepatopancreatobiliary Surgery Institute of Gansu Province | Esophageal Cancer | 12/23 | 12/23 | | |
NCT04250402: The Incidence of Gallstones After Gastric Cancer Surgery |
|
|
| Recruiting | N/A | 700 | RoW | Resection | Hepatopancreatobiliary Surgery Institute of Gansu Province | Gallstones, Gastric Cancer | 12/23 | 12/23 | | |
NCT05882006: Gallstones and Risk of Inflammatory Bowel Disease |
|
|
| Recruiting | N/A | 5000 | RoW | gallstones | Hepatopancreatobiliary Surgery Institute of Gansu Province | Inflammatory Bowel Diseases | 01/24 | 01/24 | | |
| Recruiting | N/A | 504 | RoW | Distal gastrectomy and radical resection, Total gastrectomy and radical resection | Hepatopancreatobiliary Surgery Institute of Gansu Province | Gallstone, Gastric Cancer | 01/24 | 01/24 | | |
